注射用紫杉醇（白蛋白结合型）多线治疗晚期三阴性乳腺癌的临床观察

Clinical observation of paclitaxel for injection(albumin bound)-based chemotherapy in the treatment of advanced triple negative breast cancer patients with multiple-line chemotherapy failure

目的探讨注射用紫杉醇(白蛋白结合型)三线或以上治疗晚期三阴性乳腺癌(TNBC)的疗效及安全性。方法收集16例多线治疗失败后采用注射用紫杉醇(白蛋白结合型)为基础药物治疗的晚期TNBC患者的临床资料,分析患者的近期疗效、不良反应及生存情况。结果16例晚期TNBC患者的客观缓解率为25%(4/16),疾病控制率为75%(12/16),中位无进展生存期为3个月。治疗期间患者主要的不良反应为骨髓抑制和神经毒性,其中43.75%(7/16)的患者发生3~4级中性粒细胞减少,87.50%(14/16)的患者发生1~2级贫血,75.00%(12/16)的患者发生周围神经毒性,药物相关过敏反应表现为皮疹或瘙痒。结论注射用紫杉醇(白蛋白结合型)为基础的方案用于多线治疗失败后的晚期TNBC具有较好的近期疗效及安全性。

Objective To investigate and analyze the clinical efficacy and safety of paclitaxel for injection(albumin bound)as third-line or above therapy in the treatment of advanced triple negative breast cancer(TNBC).Method The clinical data of 16 patients with advanced TNBC who had failed multiple-line chemotherapy and been treated with paclitaxel for injection(albumin-bound)-based regimen were retrospectively analyzed.The short-term efficacy,adverse reactions and survival of these patients were analyzed.Result Of the 16 patients with advanced TNBC treated with paclitaxel for injection(albumin bound)alone or in combination with other medications,the objective response rate(ORR)was 25%(4/16)and disease control rate(DCR)was 75%(12/16),besides,the median progression-free survival(PFS)time was 3 months.Myelosuppression and neurotoxicity were the main adverse reactions observed during treatment,of all patients,43.75%(7/16)developed grade 3-4 neutropenia,and 87.50%(14/16)had grade 1-2 anemia,additionally,75.00%(12/16)were with peripheral neurotoxicity.Drug-related allergic reaction was characterized by rash or pruritus.Conclusion Paclitaxel for injection(albumin bound)-based regimen for advanced TNBC with multiple-line chemotherapy failure exhibits significant short-term efficacy and safety.